Premium
Paclitaxel‐induced cutaneous lupus erythematosus in patients with serum anti‐SSA/Ro antibody
Author(s) -
ADACHI Atsuko,
HORIKAWA Tatsuya
Publication year - 2007
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/j.1346-8138.2007.00313.x
Subject(s) - paclitaxel , medicine , clearance , titer , dermatology , antibody , erythema , basal (medicine) , systemic lupus erythematosus , immunology , breast cancer , cancer , disease , urology , insulin
Two women (aged 46 and 56 years) developed annular erythema on their sun‐exposed skin, including their forearms and faces, after biweekly i.v. administration of paclitaxel for 3–4 months to treat breast cancer. Both cases showed interface changes of basal keratinocytes and high titers of serum anti‐SSA/Ro antibody. The diagnoses of paclitaxel‐induced cutaneous lupus erythematosus (LE) were made because the skin eruptions cleared rapidly within 3 weeks after the paclitaxel treatment was discontinued. Paclitaxel is proposed to be a causative agent that can provoke cutaneous LE.